These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35071006)

  • 1. Prognostic Impact of An Integrative Landscape of Clinical, Immune, and Molecular Features in Non-Metastatic Rectal Cancer.
    Iseas S; Sendoya JM; Robbio J; Coraglio M; Kujaruk M; Mikolaitis V; Rizzolo M; Cabanne A; Ruiz G; Salanova R; Gualdrini U; Méndez G; Antelo M; Carballido M; Rotondaro C; Viglino J; Eleta M; Di Sibio A; Podhajcer OL; Roca E; Llera AS; Golubicki M; Abba MC
    Front Oncol; 2021; 11():801880. PubMed ID: 35071006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Changes in CEA and CA199 Concentration After Neoadjuvant Chemoradiotherapy Could Predict the Prognosis of Stage II/III Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Total Mesorectal Excision.
    Zhao J; Zhao H; Jia T; Yang S; Wang X
    Cancer Manag Res; 2022; 14():2933-2944. PubMed ID: 36200095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy.
    Zhao JY; Tang QQ; Luo YT; Wang SM; Zhu XR; Wang XY
    World J Gastrointest Oncol; 2022 Oct; 14(10):2014-2024. PubMed ID: 36310703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative prognostic impact of Co-mutations in TGFβ and TP53 pathways in surgically resected rectal tumors following neoadjuvant chemoradiotherapy.
    Qian C; Yang W; Li M; Feng Y; Dai N; Luo H; Jian D; Li X; Yang Y; He Y; Wang D; Li C; Xiao H
    Eur J Surg Oncol; 2024 Apr; 50(4):108242. PubMed ID: 38460248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.
    Taieb J; Zaanan A; Le Malicot K; Julié C; Blons H; Mineur L; Bennouna J; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Lepage C; Emile JF; Laurent-Puig P
    JAMA Oncol; 2016 May; 2(5):643-653. PubMed ID: 26768652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of pre-neoadjuvant chemoradiotherapy inflammation biomarkers could be a prognostic marker for rectal cancer patients.
    Zhang J; Zhang L; Gou Y; Diao P; Hu Y
    Sci Rep; 2022 Mar; 12(1):4286. PubMed ID: 35277532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct clinical characteristics in stage III rectal cancer among different age groups and treatment outcomes after neoadjuvant chemoradiotherapy.
    Liu B; Luo H; Li B; Yu H; Sun R; Li J; Gao Y; Ding P; Wang X; Xiao W
    Ther Adv Med Oncol; 2024; 16():17588359241229434. PubMed ID: 38347922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety and prognosis analysis of transanal total mesorectal excision versus laparoscopic mesorectal excision for mid-low rectal cancer].
    Sun R; Cong L; Qiu HZ; Lin GL; Wu B; Niu BZ; Sun XY; Zhou JL; Xu L; Lu JY; Xiao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):522-530. PubMed ID: 35754217
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy.
    Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M
    Oncology; 2018; 95(5):270-280. PubMed ID: 29996133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
    Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
    BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between preoperative inflammatory indexes and prognosis of patients with rectal cancer and establishment of prognostic nomogram prediction model].
    Zhang L; Shi FY; Qin Q; Liu GX; Zhang HW; Yan J; Tan M; Wang LZ; Xue D; Hu CH; Zhang Z; She JJ
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):402-409. PubMed ID: 35615796
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinicopathological and prognostic features of young onset patients with middle-low rectal cancer received neoadjuvant chemoradiotherapy].
    Zhang QQ; Wu YL; Li DD; Shen SH; Fang H; Zhu YL; Zhang HZ
    Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):574-580. PubMed ID: 34034478
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
    Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
    Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
    Yang X; Rao J; Yang W; Shui R
    Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: a systematic review and meta-analysis.
    Zhao Y; Ge X; He J; Cheng Y; Wang Z; Wang J; Sun L
    World J Surg Oncol; 2019 May; 17(1):85. PubMed ID: 31118034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of CEA and CA19-9 in patients with local advanced rectal cancer receiving neoadjuvant chemoradiotherapy, radical surgery and postoperative chemotherapy.
    Shan J; Gu B; Shi L; Wang X; Ye W; Zhou W; Sun X
    Transl Cancer Res; 2021 Jan; 10(1):88-98. PubMed ID: 35116242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis.
    Zhou S; Jiang Y; Pei W; Liang J; Zhou Z
    BMC Surg; 2021 Dec; 21(1):441. PubMed ID: 34961494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.